Results 61 to 70 of about 2,002,341 (191)

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, Volume 41, Issue 6, Page 1701-1721, June 2026.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
This review summarizes key breakthrough advances in hepatocellular carcinoma (HCC) reported in 2025 and presents a multidisciplinary management framework for HCC, integrating early diagnosis, microenvironment insights, and comprehensive therapeutic strategies spanning minimally invasive surgery, locoregional interventions, and systemic pharmacotherapy.
Bo Hu, Qiang Gao
wiley   +1 more source

Radiological Loco‐Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is being diagnosed with increasing frequency worldwide. We performed a systematic review on radiofrequency (RFA), microwave (MWA), irreversible electroporation (IRE), trans‐arterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) in CCA. Thirty‐
Dimitrios Pallas, Claudia Campani, Olivier Sutter, Pierre Nahon, Nathalie Ganne‐Carrié, Olivier Seror, Jean‐Charles Nault   +6 more
wiley   +1 more source

Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy

Organ Medicine, Volume 3, Issue 1, Page 12-19, March 2026.
This multicenter retrospective study assessed preoperative immune checkpoint inhibitor (ICI) therapy in 17 hepatocellular carcinoma patients undergoing liver transplantation. All received at least one cycle of ICI‐based combination therapy before transplant and achieved a 76.5% objective response rate.
Huanquan Chen, Tianxing Dai, Jie Gao, Chuanjiang Li, Huanwei Chen, Feiwen Deng, Nan Ma, Guoying Wang   +7 more
wiley   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source

Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection

Journal of Clinical Interventional Radiology ISVIR
Purpose Yttrium 90 (Y90) transarterial radioembolization (TARE) is effective for unresectable hepatocellular carcinoma (HCC) or to bridge/downstage before transplant; however, optimal patient selection is not well-described. This study aims to
Amelia Wong, Shirley Cheng, Anthony Herrera, Linda Wong   +3 more
doaj   +1 more source

Emerging Role of MRI‐Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review

Journal of Magnetic Resonance Imaging, Volume 63, Issue 1, Page 79-97, January 2026.
ABSTRACT Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer, with significant variability in patient outcomes even within the same stage according to the Barcelona Clinic Liver Cancer staging system. Accurately predicting patient prognosis and potential treatment response prior to therapy initiation is crucial for ...
Feng Che, Jing Zhu, Qian Li, Hanyu Jiang, Yi Wei, Bin Song   +5 more
wiley   +1 more source

Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas

Canadian Journal of Gastroenterology and Hepatology, Volume 2026, Issue 1, 2026.
Background Hepatocellular carcinoma (HCC) is a lethal cancer. Early recurrence, i.e., recurrence within two years of curative treatment, is a major determinant of ultimate survival. Materials and Methods We included 625 patients with newly diagnosed early‐stage HCC, i.e., Barcelona Clinic Liver Cancer (BCLC) Stage 0 or A, and Child–Pugh Class A liver ...
Yi-Hao Yen, Kwong-Ming Kee, Chao-Hung Hung, Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Sheng-Nan Lu, Neetu Rawal   +7 more
wiley   +1 more source

SIR-Spheres 90 Yttrium-radioembolization for the treatment of unresectable liver cancers [PDF]

, 2014
Transarterial radioembolization with yttrium-90 resin microspheres (SIR-Spheres; Sirtex Medical Limited, Sydney, Australia) is a liver-directed therapy that is gaining recognition as a treatment option for liver-dominant primary and metastatic cancers ...
Golfieri Rita
core   +1 more source

Integrative Genomic Analysis Reveals Pseudouridine Modification–Related Gene Signatures Associated With Prognosis and Therapeutic Response Patterns in Hepatocellular Carcinoma

International Journal of Genomics, Volume 2026, Issue 1, 2026.
Background Hepatocellular carcinoma (HCC) is a genomically heterogeneous malignancy with substantial variability in prognosis and therapeutic response. Pseudouridine (Ψ) modification is an evolutionarily conserved RNA modification involved in RNA structure stabilization and translational regulation; however, the genomic and functional relevance of ...
Zeying Gan, Tingyuan Fan, Wenjuan Wang, Xiao Qiao, Mingming Zhao, Hao Zhang   +5 more
wiley   +1 more source